Altimmune Yönetim

Yönetim kriter kontrolleri 2/4

Altimmune CEO'su Jerry Durso, Jan2026 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.012% doğrudan sahiptir ve bu hisselerin değeri $ 45.13K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.9 yıl ve 6.4 yıldır.

Anahtar bilgiler

Jerry Durso

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	2.9yrs
Yönetim Kurulu ortalama görev süresi	6.4yrs

Son yönetim güncellemeleri

Recent updates

Altimmune: Positives And Negatives Of The IMPACT Data And Recent Updates

Dec 22

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Mar 17

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Feb 28

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Nov 13

Regulatory And Clinical Catalysts Ahead For Altimmune

Oct 28

Consider Buying Potential Takeover Target Altimmune

Oct 02

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

Sep 21

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Sep 12

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Aug 27

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Jun 24

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

May 27

Buy Altimmune's Potential Market Disruption With Pemvidutide

Apr 12

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Mar 27

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Feb 27

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Feb 12

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Feb 10

Thoroughly Derisked, Altimmune Is Now A Great Buy

Jan 10

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Oct 11

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Jun 27

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

Feb 12

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Oct 27

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Sep 15

CEO

Jerry Durso (57 yo)

no data

Görev süresi

Mr. Jerome Benedict Durso, also known as Jerry, is Chief Executive Officer and President of Altimmune, Inc. since January 1, 2026 and serves as its Chairman. He was Independent Director of Altimmune, Inc....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
M. Roberts	Chief Scientific Officer	13.1yrs	US$2.42m	0.071% $ 267.4k
Jerome Durso	Chairman	no data	Veri yok	0.012% $ 45.1k
Gregory Weaver	Chief Financial Officer	1.2yrs	Veri yok	0.022% $ 83.3k
Andrew Shutterly	Principal Financial & Accounting Officer and Corporate Controller	2.9yrs	Veri yok	0.011% $ 41.1k
Bertrand Georges	Chief Technology Officer	8.7yrs	Veri yok	Veri yok
Tony Blandin	Vice President of Quality & Compliance Management	3.9yrs	Veri yok	Veri yok
Robin Abrams	General Counsel & Chief Legal Officer	no data	Veri yok	Veri yok
Raymond Jordt	Chief Business Officer	3yrs	US$2.94m	0.035% $ 130.9k
Linda Richardson	Chief Commercial Officer	less than a year	Veri yok	Veri yok
Christophe Arbet-Engels	Chief Medical Officer	less than a year	Veri yok	Veri yok

2.9yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: ALT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jerome Durso	Chairman	less than a year	Veri yok	0.012% $ 45.1k
Mitchel Sayare	Independent Director	15.8yrs	US$255.24k	0.025% $ 95.2k
John Gill	Independent Director	21.4yrs	US$239.24k	0.012% $ 45.1k
Vipin Garg	Director	7.2yrs	US$6.09m	0.34% $ 1.3m
Philip Hodges	Independent Director	8.7yrs	US$251.24k	0.0084% $ 31.5k
Klaus Schafer	Independent Director	8.7yrs	US$240.24k	0.0088% $ 33.1k
Catherine Sohn	Independent Director	2.8yrs	US$233.99k	0.00096% $ 3.6k
Wayne Pisano	Independent Director	7.4yrs	US$244.24k	0.0081% $ 30.7k
Diane Jorkasky	Independent Director	5.7yrs	US$231.24k	0.00051% $ 1.9k
Rohit Loomba	Member of Mash Scientific Advisory Board	3.5yrs	Veri yok	Veri yok
Mazen Noureddin	Member of Mash Scientific Advisory Board	3.5yrs	Veri yok	Veri yok
Naga Chalasani	Member of Mash Scientific Advisory Board	3.5yrs	Veri yok	Veri yok

6.4yrs

Ortalama Görev Süresi

72yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/01/02 06:25
Gün Sonu Hisse Fiyatı	2026/01/02 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Altimmune, Inc. 15 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Mayank Mamtani	B. Riley Securities, Inc.
Jonathan Wolleben	Citizens JMP Securities, LLC
Liisa Bayko	Evercore ISI

Altimmune Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Altimmune, Inc. Announces CEO Changes

Altimmune, Inc. Announces the Appointment of Christophe Arbet-Engels as Chief Medical Officer, Effective October 1, 2025

Altimmune, Inc. Appoints Linda M. Richardson to the Role of Chief Commercial Officer, Effective September 16, 2025

Altimmune, Inc., Annual General Meeting, Sep 25, 2025

Altimmune Appoints Jerry Durso as Chairman, Effective August 12, 2025

Altimmune, Inc. Announces Retirement of Scott Harris as Chief Medical Officer, Effective February 28, 2026

Recent updates

Altimmune: Positives And Negatives Of The IMPACT Data And Recent Updates

Altimmune, Inc. Announces Positive Topline Results from the Impact Phase 2B Mash Trial

Altimmune, Inc. Announces CEO Changes

Altimmune, Inc. Announces Publication of Impact Phase 2B Trial Data in the Lancet and Concurrent Late-Breaking Oral Presentation At Aasld the Liver Meeting®? 2025

Altimmune, Inc. Presents Ai-Based Analysis of Liver Fibrosis Reduction from Impact Phase 2B Trial of Pemvidutide Inash in Late-Breaking Poster At Aasld the Liver Meeting®? 2025

Altimmune, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Altimmune, Inc. Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Altimmune, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Altimmune, Inc. Announces the Appointment of Christophe Arbet-Engels as Chief Medical Officer, Effective October 1, 2025

Altimmune, Inc. Appoints Linda M. Richardson to the Role of Chief Commercial Officer, Effective September 16, 2025

Altimmune, Inc. Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Altimmune, Inc., Annual General Meeting, Sep 25, 2025

Holzer & Holzer, Llc Files Shareholder Class Action Lawsuit Against Altimmune, Inc

Altimmune Appoints Jerry Durso as Chairman, Effective August 12, 2025

Levi & Korsinsky, LLP Announces Filing of Class Action Against Altimmune, Inc

Altimmune, Inc. to Report Q2, 2025 Results on Aug 12, 2025

Altimmune, Inc. Announces Initiation of Restore Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease

Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Index

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

Altimmune, Inc. Announces Initiation of RECLAIM Phase 2 Trial Evaluating Efficacy and Safety of Pemvidutide in Alcohol Use Disorder

Altimmune, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc.

Altimmune, Inc. to Report Q1, 2025 Results on May 13, 2025

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Altimmune, Inc. Announces Retirement of Scott Harris as Chief Medical Officer, Effective February 28, 2026

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Altimmune, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Altimmune, Inc. Announces Board Appointments

Altimmune, Inc. to Report Q4, 2024 Results on Feb 27, 2025

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth?

Altimmune Could Find A Partner For Its Phase 3 Exercise

Altimmune 2025: Redefining Obesity And MASH Treatment

Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer

Altimmune, Inc. Announces Successful Completion of End-of-Phase 2 Meeting with FDS for Pemvidutide in the Treatment of Obesity

Altimmune, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Regulatory And Clinical Catalysts Ahead For Altimmune

Consider Buying Potential Takeover Target Altimmune

Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (Mash)

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

Altimmune, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association’s 84th Scientific Sessions

Altimmune, Inc. Presents Data at EASL International Liver Congress™? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Pomerantz LLP Announces Filing of Class Action Against Altimmune, Inc. and Certain Officers

Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024

Buy Altimmune's Potential Market Disruption With Pemvidutide

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023

Altimmune, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

President exercised options and sold US$115k worth of stock

Thoroughly Derisked, Altimmune Is Now A Great Buy

Price target increased by 11% to US$21.29

Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations